Related Experiment Videos
Intravenous immunoglobulin therapy for refractory myositis
M Moriguchi1, T Suzuki, M Tateishi
1Institute of Rheumatology, Tokyo Women's Medical College.
Internal Medicine (Tokyo, Japan)
|August 1, 1996
Summary
Polyvalent intravenous immunoglobulin therapy (IVIG) effectively treated refractory myositis in three patients. This therapy showed sustained clinical improvement with no adverse effects, offering a new option for difficult cases.
Area of Science:
- Immunology
- Neurology
- Rheumatology
Background:
- Myositis, a group of muscle diseases, often presents as refractory to standard treatments like corticosteroids.
- Conventional therapies including corticosteroid or cyclophosphamide pulse therapy have limited efficacy in some myositis cases.
Observation:
- Three patients with refractory myositis (two with dermatomyositis, one with polymyositis) were treated with polyvalent intravenous immunoglobulin (IVIG).
- IVIG was administered at a dosage of 0.4 g/kg daily for five consecutive days.
Findings:
- Clinical improvement was observed in all patients within 1-2 months post-IVIG treatment.
- The therapeutic benefits of IVIG demonstrated durability, lasting 19-23 months in dermatomyositis patients and 12 months in the polymyositis patient.
- No adverse effects were reported during or after the IVIG treatment course.
Implications:
- Polyvalent intravenous immunoglobulin (IVIG) therapy presents a promising and safe treatment option for patients with refractory myositis.
- Further research into IVIG's efficacy and long-term outcomes in larger myositis cohorts is warranted.
- This study suggests IVIG could be a valuable addition to the therapeutic arsenal for managing complex and treatment-resistant myositis cases.